CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

22-307

MEDICAL REVIEW

CLINICAL REVIEW

Application Type	NDA 22,307
Submission Number	000
Submission Code	N
Letter Date	December 26, 2007
Stamp Date	December 26, 2007
PDUFA Goal Date	June 26, 2008
Reviewer Name	Karen A. Hicks, M.D.
Review Completion Date	April 28, 2008
Established Name	Prasugrel
(Proposed) Trade Name	Effient
Therapeutic Class	$P2Y_{12}$ ADP receptor inhibitor
Applicant	Eli Lilly and Company
Priority Designation	P
Formulation	Oral
Dosing Regimen	60 mg loading dose then 10 mg/d
Indication	Reduction of atherothrombotic events and stent thrombosis
Intended Population	Acute coronary syndromes

Table of Contents

1 Executive Summary **1**
1.1 Recommendation on Regulatory Action 1
1.2 Recommendation on Postmarketing Actions 2
1.2.1 Risk Management Activity 2
1.2.2 Required Phase 4 Commitments 2
1.3 Summary of Clinical Findings 2
1.3.1 Brief Overview of Clinical Program 2
1.3.2 Efficacy 3
1.3.3 Safety 4
1.3.4 Dosing Regimen and Administration 5
1.3.5 Drug-Drug Interactions 6
1.3.6 Special Populations 6
2 Introduction and Background **7**
2.1 Product Information 7
2.2 Currently Available Treatment for Indications 7
2.3 Availability of Proposed Active Ingredient in the United States 8
2.4 Important Issues With Pharmacologically Related Products 8
2.5 Presubmission Regulatory Activity 8
2.6 Other Relevant Background Information N/A 8
3 Significant Findings from Other Review Disciplines **8**
3.1 CMC (and Product Microbiology, if Applicable) 8
3.2 Animal Pharmacology/Toxicology 8
4 Data Sources, Review Strategy, and Data Integrity **9**
4.1 Sources of Clinical Data 9
4.2 Tables of Clinical Studies 9
4.3 Review Strategy 9
4.4 Data Quality and Integrity 9
4.5 Compliance with Good Clinical Practices 11
4.6 Financial Disclosures 11
5 Clinical Pharmacology **11**
5.1 Pharmacokinetics 11
5.1.1 Salt to Base Conversion 12
5.1.2 Relationship Between Body Weight and Exposure 13
5.2 Pharmacodynamics 14
5.3 Exposure-Response Relationships 14
6 Integrated Review of Efficacy **15**
6.1 Indication 15
6.1.1 Methods 15
6.1.2 General Discussion of Endpoints 15
6.1.3 Study Design 15
6.1.4 Efficacy Findings 19
6.1.5 Clinical Microbiology N/A 32
6.1.6 Efficacy Conclusions (Study TAAL) 32
7 Integrated Review of Safety **32**
7.1 Methods and Findings 32

7.1.1 Deaths 33
7.1.2 Other Serious Adverse Events 35
7.1.3 Dropouts and Other Significant Adverse Events 47
7.1.4 Common Adverse Events 49
7.1.5 Less Common Adverse Events 49
7.1.6 Laboratory Findings 50
7.1.7 Vital Signs 50
7.1.8 Electrocardiograms (ECGs) 50
7.1.9 Immunogenicity N/A 51
7.1.10 Human Carcinogenicity (Please see Section 7.1.2.2 for further details) 51
7.1.11 Special Safety Studies N/A 51
7.1.12 Withdrawal Phenomena and/or Abuse Potential N/A 51
7.1.13 Human Reproduction and Pregnancy Data 51
7.1.14 Assessment of Effect on Growth N/A 51
7.1.15 Overdose Experience 51
7.1.16 Postmarketing Experience 51
7.2 Adequacy of Patient Exposure and Safety Assessments 51
7.2.1 Demographics 53
7.2.2 Adequacy of Overall Clinical Experience 54
7.2.3 Adequacy of Special Animal and/or In Vitro Testing 54
7.2.4 Adequacy of Routine Clinical Testing 54
7.2.5 Adequacy of Metabolic, Clearance, and Interaction Workup 54
7.2.6 Adequacy of Evaluation for Potential Adverse Events for Any New Drug and Particularly for Drugs in the Class Represented by the New Drug; Recommendations for Further Study 55
7.2.7 Assessment of Quality and Completeness of Data 55
7.2.8 Additional Submissions, Including Safety Update 55

8 Additional Clinical Issues 55

8.1 Conclusions 55

9 Appendices (Review Of Individual Study Reports) 56

9.1 Study H7T-MC-TAAL (Primary) (Clinical Study Report: "A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who are to Undergo Percutaneous Coronary Intervention/TIMI 38") (Study Dates: November 5, 2004 – July 22, 2007) (Date of Report: November 28, 2007) 56
9.1.1 Protocol, Amendment, and Post Hoc Changes 56
9.1.2 Study Design 57
9.1.3 Study Population 57
9.1.4 Objectives 58
9.1.5 Inclusion/Exclusion Criteria 60
9.1.6 Study Plan 62
9.1.7 Schedule of Evaluations and Procedures 65
9.1.8 Endpoints 68
9.1.9 Clinical Events Committee (CEC) 71
9.1.10 Statistical Considerations 71
9.1.11 Results 76
9.2 Study H7T-MC-TABL(Clinical Study Report: "PRasugrel IN Comparison to Clopidogrel for Inhibition of Platelet Activation and AggrEgation (PRINCIPLE) – TIMI 44") (Study Dates: August 24, 2006 – June 20, 2007) (Date of Report: October 1, 2007) 106
9.2.1 Protocol, Amendment, and Post Hoc Changes 106
9.2.2 Study Design 106
9.2.3 Study Population 106
9.2.4 Objectives 106
9.2.5 Inclusion/Exclusion Criteria 107
9.2.6 Study Plan 108

9.2.7 Schedule of Evaluations and Procedures 110
9.2.8 Endpoints 112
9.2.9 Safety Measures 113
9.2.10 Definitions 113
9.2.11 Statistical Considerations 115
9.2.12 Results 116
9.2.13 Summary (TABL) 135
9.3 Study H7T-MC-TAAH (Clinical Study Report: "A Double-Blind, Randomized, Multicenter, Dose-Ranging Trial of CS-747 (LY640315) Compared With Clopidogrel in Subjects Undergoing Percutaneous Coronary Intervention (Joint Utilization of Medications to Block Platelets Optimally) (JUMBO-TIMI 26)") (Study Dates: April 15, 2003 – January 6, 2004) (Date of Report: June 24, 2005) 136
9.3.1 Protocol, Amendment, and Post Hoc Changes 136
9.3.2 Study Design 136
9.3.3 Study Population 136
9.3.4 Objectives 136
9.3.5 Inclusion/Exclusion Criteria 137
9.3.6 Study Plan 138
9.3.7 Schedule of Evaluations and Procedures 139
9.3.8 Endpoints 141
9.3.9 Statistical Considerations 141
9.3.10 Results 143
9.4 Line-by-Line Labeling Review 145

10 References 145

Table of Tables

Table 1. Sponsor's Analysis: Number and Percentage of Subjects Reaching the Composite Endpoint of CV Death, Nonfatal MI or Nonfatal Stroke Using the Definition of Peri-Procedural Myocardial Infarction Prior to Protocol Amendment (CEC Adjudicated) (All Randomized Subjects) (TAAL) 3
Table 2. Sponsor's Analysis: Number and Percentage of Subjects Reaching the Composite Endpoint of CV Death, Nonfatal MI, or Nonfatal Stroke Using the Expanded Definition (CEC Adjudicated) (All Randomized Subjects) (TAAL) 3
Table 3. Sponsor's Analysis: CEC Adjudicated Non-CABG-Related Bleeding (TAAL) 4
Table 4. Sponsor's Analysis: CEC-Adjudicated CABG-Related Bleeding Events Through Study End (Overall) (TAAL) 4
Table 5. FDA Subgroup Analysis: Composite of Cardiovascular Death, Nonfatal Myocardial Infarction, or Nonfatal Stroke at a Median of 12 Months of Follow-Up by Age (TAAL) 6
Table 6. FDA Subgroup Analysis: Composite of Cardiovascular Death, Nonfatal Myocardial Infarction, or Nonfatal Stroke at a Median of 12 Months of Follow-up in Patients With and Without a Prior History of Transient Ischemic Attack/Cerebrovascular Accident (TAAL) 7
Table 7. Summary of the Pivotal Phase 3 and Phase 2 Studies 9
Table 8. Sponsor's Analysis: Number and Percentage of Subjects Reaching the Composite Endpoint of CV Death, Nonfatal MI or Nonfatal Stroke Using the Definition of Peri-Procedural Myocardial Infarction Prior to Protocol Amendment (CEC Adjudicated) (All Randomized Subjects) (TAAL) 19
Table 9. Sponsor's Analysis: Number and Percentage of Subjects Reaching the Composite Endpoint of CV Death, Nonfatal MI, or Nonfatal Stroke Using the Expanded Definition of Peri-Procedural Myocardial Infarction After Protocol Amendment (CEC Adjudicated) (All Randomized Subjects) (TAAL) 20
Table 10. Sponsor's Analysis: Nonfatal MI (TAAL) 20
Table 11. Sponsor's Analysis: Summary of Nonfatal Myocardial Infarction 21
Table 12. FDA Subgroup Analysis of Primary Endpoint by Age (Composite of CV Death, Nonfatal MI, or Nonfatal Stroke) (TAAL) 22
Table 13. FDA Subgroup Analysis of Primary Endpoint by Sex (Composite of CV Death, Nonfatal MI, or Nonfatal Stroke) (TAAL) 22
Table 14. FDA Subgroup Analysis of Primary Endpoint by Ethnicity (Composite of CV Death, Nonfatal MI, or Nonfatal Stroke) (TAAL) 23
Table 15. FDA Subgroup Analysis of Primary Endpoint by Prior History of Transient Ischemic Attack or Stroke (Composite of CV Death, Nonfatal MI, or Nonfatal Stroke) (TAAL) 23
Table 16. FDA Subgroup Analysis of Primary Endpoint by Timing of Loading Dose (Composite of CV Death, Nonfatal MI, or Nonfatal Stroke) (TAAL) 24
Table 17. FDA Subgroup Analysis of Primary Endpoint by Use of Proton Pump Inhibitors (Composite of CV Death, Nonfatal MI, or Nonfatal Stroke) (TAAL) 26
Table 18. FDA Subgroup Analysis of Primary Endpoint by Weight (Composite of CV Death, Nonfatal MI, or Nonfatal Stroke) (TAAL) 26
Table 19. Sponsor's Analysis: Number and Percentage of Subjects Reaching the Secondary Composite Endpoints--CEC Adjudicated (All Randomized Subjects) (TAAL) 28
Table 20. Sponsor's Analysis: Number and Percentage of Subjects Reaching Secondary and Other Efficacy Endpoints--CEC Adjudicated (All Randomized Subjects) (TAAL) 30
Table 21. Sponsor's Analysis: Summary of CEC-Adjudicated Deaths (All Randomized Subjects) (TAAL) 34
Table 22. Sponsor's Analysis: CEC Adjudicated Non-CABG-Related Bleeding (TAAL) 35
Table 23. Sponsor's Analysis: CEC-Adjudicated CABG-Related Bleeding Events Through Study End (Overall) (TAAL) 36
Table 24. Sponsor's Analysis: Number and Percentage of Subjects with CABG-Related TIMI Major Bleeding Events Through Study End (CEC-Adjudicated) (All Treated Subjects) 36
Table 25. Summary of Intracranial Hemorrhages While at Risk (CEC Adjudicated) (All Treated All ACS Subjects) (TAAL) 37
Table 26. FDA Analysis: Number and Percentage of Subjects with Bleeding Events (TAAL) 38
Table 27. Number and Percentage of Subjects with Bleeding by Organ System (TAAL) 39

Table 28. FDA Analysis: Relative Risk (95% CI) of Bleeding on Prasugrel Compared to Clopidogrel (TAAL) 39
Table 29. Relative Risk (95% CI) of Bleeding on Prasugrel Compared to Clopidogrel (TAAL) 40
Table 30. Number of New First Cancers by Site and Treatment (TAAL) 43
Table 31. Primary Reason for Premature Study Drug Discontinuation (All ACS) (TAAL) 48
Table 32. Overview of Treatment-Emergent Adverse Events Through Study End (All ACS Population) (TAAL) ..48
Table 33. QTIRT Analysis: The Point Estimates and the 90% Cis Corresponding to the Largest Upper Bounds for Prasugrel 80 mg and the Largest Lower Bounds for Moxifloxacin (H7t-EW-TAAP) 51
Table 34. Exposure to Prasugrel (by Days) in Subjects with Atherosclerosis in the Primary and Secondary Safety Databases 52
Table 35. Prasugrel Exposure in Clinical Pharmacology Studies 53
Table 36. Demographics and Baseline Characteristics (All Randomized All ACS Subjects) (TAAL) 53
Table 37. TIMI Hemorrhage Criteria[a] 60
Table 38. TIMI Risk Score for UA/NSTEMI 61
Table 39. New York Heart Association Congestive Heart Failure (NYHA CHF) Classifications 61
Table 40. Study Schedule for Study H7T-MC-TAAL 66
Table 41. Interim Analyses by the Data Monitoring Committee 74
Table 42. Calculation of TIMI RISK SCORE for Subjects with UA/NSTEMI or STEMI 75
Table 43. Sponsor's Analysis: Summary of Protocol Violations Identified from the Clinical Database (TAAL) 77
Table 44. Sponsor's Analysis: Number of Protocol Violations Identified by Site Monitoring (TAAL) 77
Table 45. Sponsor's Analysis: Subject Disposition (All Randomized Subjects) (TAAL) 79
Table 46. Sponsor's Analysis: Kaplan-Meier Estimates for the Incidence of Withdrawal of Consent or Lost-to-Follow-Up (TAAL) 80
Table 47. Demographics and Baseline Characteristics (TAAL) 81
Table 48. Index Procedure (All Randomized Subjects) (TAAL) 93
Table 49. Duration of Follow-Up (All Randomized Subjects) (TAAL) 96
Table 50. Number and Percentage of Subjects Reaching the Composite Endpoint of CV Death, Nonfatal MI, or Nonfatal Stroke--CEC Adjudicated (All Randomized Subjects) (TAAL) 96
Table 51. FDA Subgroup Analyses of Primary Endpoint (TAAL) 98
Table 52. Study Schedule Protocol PRINCIPLE - TIMI 44 111
Table 53. TIMI Hemorrhage Criteria (TAAL) 114
Table 54. Protocol Violations (TABL) 116
Table 55. Demographic and Baseline Characteristics (TABL) 120
Table 56. Sponsor's Analysis: IPA by LTA with 20 μM ADP 6 Hours post LD (Acute Phase Population) (TABL) 121
Table 57. Sponsor's Analysis: IPA to 20 μM ADP at 14 ± 2 days (Chronic Phase Population) (TABL) 122
Table 58. Sponsor's Analysis: IPA to 20 μM ADP at 30 min, 2 hours, 18 to 24 hours Following Loading Dose of Study Drug 122
Table 59. Sponsor's Analysis: Inhibition of Platelet Aggregation with 5 μM Adenosine Diphosphate (Acute Phase Population) (TABL) 123
Table 60. Sponsor's Analysis: Maximum Platelet Aggregation to 20 μM ADP at 30 minutes, 2 hours, 6 hours and 18 to 24 hours following Loading Dose of Study Drug (Acute Phase Population) (TABL) 124
Table 61. Sponsor's Analysis: Maximal Platelet Aggregation to 5 μM Adenosine Disphosphate (Acute Phase Population) (TABL) 125
Table 62. Sponsor's Analysis: VerifyNow™ $P2Y_{12}$ Percent Inhibition Data 126
Table 63. Sponsor's Analysis: Thienopyridine Hyporesponsiveness to 20 μM ADP After LD and During MD ...127
Table 64. Sponsor's Analysis: VASP Platelet Reactivity Index (PRI %) Throughout Study 128
Table 65. Sponsor's Analysis: Clinical Efficacy Measures Occurring at any Time During the Study (On-Treatment Population) (TABL) 130
Table 66. Exposure to Study Medication (On Treatment Population) (TABL) 131
Table 67. Sponsor's Analysis: Non-CABG-Related TIMI Clinically Significant Bleeding Events up to Day 15 Visit (Number and Percentage of Subjects) (On-Treatment Population) (TABL) 131
Table 68. Sponsor's Analysis: Overview of Adverse Events (Number and Percentage of Subjects) (On-Treatment Population) (TABL) 133

Table 69. Sponsor's Analysis: Serious Adverse Events by System Organ Class and Preferred Term (Number and Percentage of Subjects) (All Randomized Subjects) 134
Table 70. Treatment Regimen (TAAH) 138
Table 71. Study Schedule (TAAH) 140
Table 72. TIMI Hemorrhage Criteria 141
Table 73. Subject Demographics and Baseline Characteristics (Evaluable Set) 144

Table of Figures

Figure 1. Kaplan-Meier (K-M) Incidence Plot for All New Solid Cancers Diagnosed After 7 Days in TRITON.....5
Figure 2. Clearance of R-138727 Increases with Increase in body weight.....13
Figure 3. Increased Exposures of R-138727 with Decreased Body Weight (TAAL).....13
Figure 4. Risk for TIMI Major Bleeding is Higher in Patients with Body Weight < 60 kg.....14
Figure 5. Simulation (N=2000) of the Proposed 5 mg Maintenance Dose in Patients with Body Weight < 60 kg ((CL = 123 x $(WT/85)^{0.798}$; Between-subject variability (%CV) = 24%) (Study TABR).....14
Figure 6. Study H7T-MC-TAAL Study Design.....16
Figure 7. Study H7T-MC-TAAL Treatment Plan.....17
Figure 8. Enrollment of Subjects (TAAL).....18
Figure 9. Kaplan-Meier Estimate of the Incidence of the Composite Endpoint of Cardiovascular Death, Nonfatal MI, or Nonfatal Stroke (CEC Adjudicated) (All Randomized UA/NSTEMI Subjects) (TAAL).....21
Figure 10. Incidence of Cardiovascular Death, Nonfatal MI, or Nonfatal Stroke (TAAL) Based on Timing of Loading Dose.....25
Figure 11. Timing of Loading Dose and Effect on Primary Endpoint (TAAL).....25
Figure 12. FDA Analysis: Kaplan-Meier Plot for Any Bleeding Event (Day 0 to 360) (TAAL).....40
Figure 13. FDA Analysis: Kaplan-Meier Plot for Any Bleeding Event (Day 0 to 30) (TAAL).....41
Figure 14. FDA Analysis: Kaplan-Meier Plot for Serious Bleeding Events (Day 0 to 360).....41
Figure 15. Kaplan-Meier Plot for Serious Bleeding Events (Day 0 to 30).....42
Figure 16. Kaplan-Meier Plot for Gastrointestinal Bleeding Events (Day 0 to 360).....42
Figure 17. Kaplan-Meier Plot for Gastrointestinal Bleeding (Day 0 to 90).....43
Figure 18. Kaplan-Meier (K-M) Incidence Plot for All New Solid Cancers Diagnosed After 7 Days in TRITON...44
Figure 19. Kaplan-Meier Incidence Plot for All New Solid Cancers in Women After 7 Days.....45
Figure 20. Kaplan-Meier Incidence Plot for All New Solid Cancers in Men After 7 Days.....45
Figure 21. Kaplan-Meier Incidence Plot for New Gastrointestinal/Genitourinary Cancers Diagnosed After 7 Days in TRITON.....46
Figure 22. Kaplan-Meier Incidence Plot for New Non-Gastrointestinal/Genitourinary Cancers Diagnosed After 7 Days in TRITON.....46
Figure 23. Study H7T-MC-TAAL Study Design.....63
Figure 24. Study H7T-MC-TAAL Treatment Plan.....64
Figure 25. Evaluate the Superiority of Prasugrel Compared to Clopidogrel at a One-Sided Alpha Level of 0.025 in UA/NSTEMI Cohort Relative to.....73
Figure 26. Enrollment of Subjects (TAAL).....78
Figure 27. Hazard Ratio and 95% Confidence Interval for the Composite Endpoint of CV Death, Nonfatal MI, or Nonfatal Stroke--CEC Adjudicated (All Randomized UA/NSTEMI Subjects) (TAAL).....97
Figure 28. Study Design (Protocol H7T-MC-TABL).....109
Figure 29. Schedule of Evaluations and Procedures (Protocol H7T-MC-TABL).....110
Figure 30. Subject Disposition (TABL).....118
Figure 31. Study Populations (TABL).....119
Figure 32. H7T-MC-TAAH Study Design.....139
Figure 33. Subject Disposition (All Randomized Set) (TAAH).....143
Figure 34. Significant (TIMI non-CABG Major + Minor) Bleeding at 30-Day Visit (%).....144
Figure 35. MACE (Death + MI + Stroke +CTVT + Recurrent Ischemia) at 30-Day Visit (%) (TAAH).....145

Abbreviations

ABT=All But TAAL studies
ACS=acute coronary syndromes
ACT=activated clotting time
ADP=adenosine diphosphate
AE=adverse event
Afib=atrial fibrillation
Afl=atrial flutter
ALT=alanine aminotransaminase
ARB=angiotensin receptor blockers
ARC=Academic Research Consortium
ASA= aspirin
AST=aspartate aminotransaminase
AUC=area under the curve
BMS=bare metal stent
BP=blood pressure
BUN=blood urea nitrogen
CABG=coronary artery bypass graft surgery
CAD=coronary artery disease
CBC=complete blood count
CEC=Clinical Endpoints Committee
CHF=congestive heart failure
CI=confidence interval
CIB=Clinical Investigator's Brochure
CIE=cardiac ischemic events
CK=creatine kinase
CK-MB=creatine kinase-myocardial bands
Completion of the PCI procedure=defined as 60 minutes after the subject leaves the cardiac catheterization laboratory
COX2=cyclooxygenase-2
CRF=Case report form
CRO=Contract research organization
CS-747=prasugrel
CT=computed tomography
CURE=The Clopidogrel in Unstable angina to prevent Recurrent Events Study
CV=cardiovascular
CVA=cerebrovascular accident
DBP=diastolic blood pressure
DES=drug eluting stent
DM=diabetes mellitus
DMC=Data Monitoring Committee
ECG=electrocardiogram
End of Study (Trial)=End of study (trial) is the date of the last visit shown in the study schedule of the last subject active in the study
GP=glycoprotein
H2=histamine 2 receptor
Hct=hematocrit
HDL=high density lipoprotein
Hgb=hemoglobin
HMG Co-A=3 hydroxy-3-methylglutaryl coenzyme A
HTN=hypertension

HR=heart rate
ICH=intracranial hemorrhage
INR=International Normalized Ratio
Index procedure=PCI during the initial hospitalization
IPA=inhibition of platelet aggregation
IRB/ERB=Institutional review board/ethical review board
ITT=intent-to-treat
IVRS=Interactive Voice Response System
JUMBO=The Joint Utilization of Medications to Block Platelets Optimally study
LBBB=left bundle branch block
LD=loading dose
MACE=major adverse cardiovascular events
MD=maintenance dose
MI=myocardial infarction
MPA=maximum platelet aggregation
MRI=magnetic resonance imaging
N/A=not applicable
NE=not evaluated
NQWMI=non-Q-wave myocardial infarction
NSAIDS=nonsteroidal anti-inflammatory drugs
NSTEMI=non-ST-segment elevation myocardial infarction
NYHA CHF=New York Heart Association Congestive Heart Failure
PCI=percutaneous coronary intervention
PPI=proton pump inhibitors
QD=once daily
QwMI=Q-wave myocardial infarction
RBC=red blood cells
SAE=serious adverse event
SAP=Statistical Analysis Plan
SBP=systolic blood pressure
SGOT=serum glutamic oxaloacetic transaminases
SGPT=serum glutamic pyruvic transaminases
SOC=system organ class
STEMI=ST-segment elevation myocardial infarction
TAAL=Study H7T-MC-TAAL. A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are To Undergo Percutaneous Coronary Intervention/TIMI-38
TEAE=Treatment-emergent adverse event. Any untoward medical occurrence that either occurs or worsens at any time after treatment baseline and which does not necessarily have to have a causal relationship with this treatment.
TESAE=treatment emergent serious adverse event
TIA=transient ischemic attack
TIMI=The TIMI Study Group. Named for a series of national clinical studies know as the TIMI (Thrombolysis in Myocardial Infarction) studies launched in 1984 by Brigham and Women's Hospital
TVR=target vessel revascularization
UA=unstable angina
UA/NSTEMI=unstable angina and non-ST-segment elevation myocardial infarction
ULN=upper limit of normal
US=United States of America
UTVR=urgent target vessel revascularization
Vfib=ventricular fibrillation
WBC= white blood cells